MBX Biosciences (MBX) Assets Average (2024 - 2026)

MBX Biosciences has disclosed Assets Average across 3 years of filings, most recently posting $418.9 million for Q1 2026.

• Assets Average for Q1 2026 came in at $418.9 million, up 62.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $418.9 million (up 62.86% YoY), and the FY2025 annual result was $326.8 million, up 85.33% from the prior year.
• Assets Average came in at $418.9 million for Q1 2026 at MBX Biosciences, up from $392.6 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $418.9 million in Q1 2026 to a low of $238.7 million in Q2 2025.
• The 3-year median for Assets Average is $295.6 million (2024), against an average of $316.5 million.
• Across the five-year window, Assets Average soared 42.52% in 2025 and surged 62.86% in 2026, its largest moves.
• MBX Biosciences' Assets Average stood at $275.5 million in 2024, then jumped by 42.52% to $392.6 million in 2025, then gained by 6.7% to $418.9 million in 2026.
• The last three Assets Average figures came in at $418.9 million (Q1 2026), $392.6 million (Q4 2025), and $315.8 million (Q3 2025), per Business Quant data.